KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Total Debt (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Total Debt data on record, last reported at $1.1 billion in Q3 2025.

  • For Q3 2025, Total Debt fell 12.74% year-over-year to $1.1 billion; the TTM value through Sep 2025 reached $1.1 billion, down 12.74%, while the annual FY2024 figure was $1.1 billion, 8.15% down from the prior year.
  • Total Debt reached $1.1 billion in Q3 2025 per SRPT's latest filing, down from $1.1 billion in the prior quarter.
  • Across five years, Total Debt topped out at $1.5 billion in Q4 2022 and bottomed at $1.1 billion in Q3 2025.
  • Average Total Debt over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2025.
  • Peak YoY movement for Total Debt: soared 58.6% in 2021, then decreased 19.84% in 2023.
  • A 5-year view of Total Debt shows it stood at $1.1 billion in 2021, then surged by 40.79% to $1.5 billion in 2022, then fell by 19.83% to $1.2 billion in 2023, then fell by 8.15% to $1.1 billion in 2024, then fell by 5.8% to $1.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $1.1 billion in Q3 2025, $1.1 billion in Q2 2025, and $1.1 billion in Q1 2025.